FAAM EUROBAT 2024

Back
21 - 23 November 2024 Athens, Greece

FT1 - Allergen immunotherapy and Anaphylaxis

Friday 22 Nov, 08:30 AM - 10:00 AM Athens, Greece
Ballroom I Flash Talk
08:30 FT-02
Clinical characteristics of food anaphylaxis in patients with hereditary alpha-tryptasemia
08:37 FT-03
Basophil activation test as a marker of desensitization in Very Low-Dose Multi-Nut Immunotherapy and Very Low-Dose Peanut Oral Immunotherapy
08:44 FT-04
Management of positive challenges in Allergy Day Hospital through the eyes of Food Allergy Severity Score (FASS score)
08:51 FT-05
Is milk oral immunotherapy using a home up-dosing protocol a viable and safe treatment for the older milk allergic child?
08:58 FT-06
IgG-mediated anaphylaxis in a mouse model of peanut allergy
09:05 FT-07
Evaluation of the IgEs amount and basophil activity changes during walnut oral immunotherapy
09:12 FT-08
Prescription and use of epinephrine autoinjectors in pediatric anaphylaxis
09:19 FT-09
SCHOOL ALERT: Ensuring Safety for Students with Severe Allergies
09:26 FT-10
Characterising the severity of probable IgE-mediated food allergy in UK adults
09:33 FT-11
Tryptase and Complement as Biomarkers of Severe Anaphylaxis: A Study of 126 Patients at a Hospital Clinic (Barcelona, Spain)
09:40 FT-12
The NAples Pediatric Food Allergy score: a multivariable model for the prediction of food allergy in children
09:47 FT-13
Cannabinoid WIN55212-2 impairs peanut allergic-sensitization, inhibits peanut-induced anaphylaxis and promotes regulatory T cell generation

Chairs

Speakers